Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson sits down with Jonathan Jackson in the Proactive studio to discuss how the company and its technology partner v2vmedtech, inc have reached the concept lock stage on the first phase of development for the next generation Transcatheter Edge to Edge Repair (TEER) system for mitral and tricuspid valve regurgitation.
The two structural heart companies are developing the new TEER system for patients with mitral and tricuspid valve disease, where damaged valves cause blood to leak between the ventricles and atriums of the heart. TEER is becoming the primary intervention for this disease but current systems have limitations affecting procedural outcomes or patient eligibility. Anteris's new VClip™ aims to address these needs and provide better patient outcomes.
Paterson noted how Dr Vinayak Bapat, v2vmedtech’s chief medical officer, highlighted the importance of the concept lock as proof of concept data, noting rapid progress due to collaboration with engineers and leading interventional cardiologists. Approximately 2.5% of the US population has valvular heart disease, with significant mortality rates. The Baker Heart and Diabetes Research Institute estimates up to 600,000 Australians were living with heart valve disease in 2021, with many undiagnosed.
This is a major milestone for advancing VClip™ towards a first-in-human study.
Anteris is also developing DurAVR™, a transcatheter heart valve for treating aortic stenosis, designed with bioengineered tissue to mimic a healthy aortic valve's performance.
#ProactiveInvestors #AnterisTechnologies #ASX #OTC #v2vmedtech, #TEER, #ValveRegurgitation, #MitralValve, #TricuspidValve, #HeartDisease, #VClip, #MedicalInnovation, #Cardiology, #HeartValveDisease, #Healthcare, #Bioengineering, #CardiacSurgery, #Transcatheter, #AorticStenosis, #DurAVR, #ValvularHeartDisease, #MedicalResearch, #InterventionalCardiology
#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
30 июн 2024
